Published in PLoS One on February 27, 2014
Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology (2014) 1.44
Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis (2016) 0.76
External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort). BMC Pulm Med (2016) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Standardisation of spirometry. Eur Respir J (2005) 48.20
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 9.69
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax (1999) 8.63
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax (2005) 7.39
Survival model predictive accuracy and ROC curves. Biometrics (2005) 7.26
Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ (1996) 6.25
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet (2009) 5.51
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest (2002) 3.82
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54
Mortality after hospitalization for COPD. Chest (2002) 3.37
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00
Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax (2009) 2.27
Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J (2012) 2.18
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med (2010) 2.09
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 2.02
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest (2013) 1.51
Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med (2009) 1.51
Cardiovascular comorbidity in COPD: systematic literature review. Chest (2013) 1.38
Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest (2012) 1.33
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol (2012) 1.29
Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm Med (2013) 1.21
Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration (2011) 1.08
Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med (2013) 1.08
The SAFE (SGRQ score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J (2007) 1.05
Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One (2012) 1.04
Predictors of mortality in patients with stable COPD. J Gen Intern Med (2008) 1.01
Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med (2013) 0.93
Prognosis of chronic obstructive pulmonary disease: the Dutch experience. Am Rev Respir Dis (1989) 0.93
COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med (2013) 0.92
Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study. Respir Res (2012) 0.88
Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J Epidemiol (2012) 0.87
Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD. Chest (2010) 0.86
The effect of airflow limitation on the cause of death in patients with COPD. Chron Respir Dis (2010) 0.83
Association between lung capacity measurements and abnormal glucose metabolism: findings from the Crossroads study. Diabet Med (2013) 0.82
Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace (2013) 0.82
Respiratory function as a marker of bone health and fracture risk in an older population. J Bone Miner Res (2009) 0.80
[Post-hospital mortality in patients re-admitted due to COPD. Utility of BODE index]. Rev Clin Esp (2009) 0.78
The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis (2015) 0.91
Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today (2014) 0.90
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis (2016) 0.76
POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis (2016) 0.76
Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Adv Ther (2016) 0.75
Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Adv Ther (2017) 0.75
Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. J Am Med Dir Assoc (2017) 0.75
GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J (2017) 0.75
Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis (2017) 0.75